LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States.

    Roe, Molly K / Huffman, Elise R / Batista, Yara S / Papadeas, George G / Kastelitz, Sydney R / Restivo, Anna M / Stobart, Christopher C

    Emerging infectious diseases

    2023  Volume 29, Issue 1, Page(s) 1–7

    MeSH term(s) United States/epidemiology ; Humans ; Cell Line ; Influenza, Human ; Thogotovirus
    Language English
    Publishing date 2023-01-01
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/eid2901.212295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4778: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Targeting novel structural and functional features of coronavirus protease nsp5 (3CL

    Roe, Molly K / Junod, Nathan A / Young, Audrey R / Beachboard, Dia C / Stobart, Christopher C

    The Journal of general virology

    2021  Volume 102, Issue 3

    Abstract: Coronavirus protease nsp5 ( ... ...

    Abstract Coronavirus protease nsp5 (M
    MeSH term(s) Amino Acid Sequence ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/virology ; Coronavirus/enzymology ; Coronavirus/metabolism ; Coronavirus 3C Proteases/antagonists & inhibitors ; Coronavirus 3C Proteases/chemistry ; Coronavirus 3C Proteases/genetics ; Coronavirus 3C Proteases/metabolism ; Humans ; Phylogeny ; SARS-CoV-2/enzymology ; SARS-CoV-2/metabolism ; Viral Nonstructural Proteins/antagonists & inhibitors ; Viral Nonstructural Proteins/metabolism ; Viral Protease Inhibitors/therapeutic use
    Chemical Substances Antiviral Agents ; Viral Nonstructural Proteins ; Viral Protease Inhibitors ; 3C-like proteinase, SARS-CoV-2 (EC 3.4.22.-) ; Coronavirus 3C Proteases (EC 3.4.22.28)
    Language English
    Publishing date 2021-01-28
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 219316-4
    ISSN 1465-2099 ; 0022-1317
    ISSN (online) 1465-2099
    ISSN 0022-1317
    DOI 10.1099/jgv.0.001558
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 610: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.

    Roe, Molly K / Perez, Maria A / Hsiao, Hui-Mien / Lapp, Stacey A / Sun, He-Ying / Jadhao, Samadhan / Young, Audrey R / Batista, Yara S / Reed, Ryan C / Taz, Azmain / Piantadosi, Anne / Chen, Xuemin / Liang, Bo / Koval, Michael / Snider, Timothy A / Moore, Martin L / Anderson, Evan J / Anderson, Larry J / Stobart, Christopher C /
    Rostad, Christina A

    The Journal of infectious diseases

    2022  

    Abstract: Background: RSV is a leading viral respiratory pathogen in infants. The objective of this study was to generate RSV live-attenuated vaccine (LAV) candidates by removing the G-protein mucin domains to attenuate viral replication while retaining ... ...

    Abstract Background: RSV is a leading viral respiratory pathogen in infants. The objective of this study was to generate RSV live-attenuated vaccine (LAV) candidates by removing the G-protein mucin domains to attenuate viral replication while retaining immunogenicity through de-shielding of surface epitopes.
    Methods: Two LAV candidates were generated from recombinant RSV A2-line19F by deletion of the G-protein mucin domains (A2-line19F-G155) or deletion of the G-protein mucin and transmembrane domains (A2-line19F-G155S). Vaccine attenuation was measured in BALB/c mouse lungs by fluorescent focus unit (FFU) assays and RT-PCR. Immunogenicity was determined by measuring serum binding and neutralizing antibodies in mice following prime/boost on days 28 and 59. Efficacy was determined by measuring RSV lung viral loads on day 4 post-challenge.
    Results: Both LAVs were undetectable in mouse lungs by FFU assay and elicited similar neutralizing antibody titers compared to A2-line19F on days 28 and 59. Following RSV challenge, vaccinated mice showed no detectable RSV in the lungs by FFU assay and a significant reduction in RSV RNA in the lungs by RT-PCR of 560-fold for A2-line19F-G155 and 604-fold for A2-line19F-G155S compared to RSV-challenged, unvaccinated mice.
    Conclusions: Removal of the G-protein mucin domains produced RSV LAV candidates that were highly attenuated with retained immunogenicity.
    Language English
    Publishing date 2022-10-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3019-3
    ISSN 1537-6613 ; 0022-1899
    ISSN (online) 1537-6613
    ISSN 0022-1899
    DOI 10.1093/infdis/jiac382
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.50: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 445: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.

    Chambers, Setsuko K / Clouser, Mary C / Baker, Amanda F / Roe, Denise J / Cui, Haiyan / Brewer, Molly A / Hatch, Kenneth D / Gordon, Michael S / Janicek, Mike F / Isaacs, Jeffrey D / Gordon, Alan N / Nagle, Raymond B / Wright, Heather M / Cohen, Janice L / Alberts, David S

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2010  Volume 16, Issue 21, Page(s) 5320–5328

    Abstract: Purpose: This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also done.: Experimental design: Forty ...

    Abstract Purpose: This phase II trial evaluated bevacizumab plus erlotinib in platinum-resistant ovarian cancer; exploratory biomarker analyses, including that of tumor vascular endothelial growth factor A (VEGF-A), were also done.
    Experimental design: Forty heavily pretreated patients received erlotinib (150 mg/d orally) and bevacizumab (10 mg/kg i.v.) every 2 weeks until disease progression. Primary end points were objective response rate and response duration; secondary end points included progression-free survival (PFS), toxicity, and correlations between angiogenic protein levels, toxicity, and efficacy.
    Results: Grade 3 toxicities included skin rash (n = 6), diarrhea (n = 5), fatigue (n = 4), and hypertension (n = 3). Grade 4 toxicities were myocardial infarction (n = 1) and nasal septal perforation (n = 1). Only one grade 3 fistula and one grade 2 bowel perforation were observed. Nine (23.1%) of 39 evaluable patients had a response (median duration, 36.1+ weeks; one complete response), and 10 (25.6%) patients achieved stable disease, for a disease control rate of 49%. Median PFS was 4 months, and 6-month PFS was 30.8%. Biomarker analyses identified an association between tumor cell VEGF-A expression and progression (P = 0.03); for every 100-unit increase in the VEGF-A score, there was a 3.7-fold increase in the odds of progression (95% confidence interval, 1.1-16.6).
    Conclusions: Bevacizumab plus erlotinib in heavily pretreated ovarian cancer patients was clinically active and well tolerated. Erlotinib did not seem to contribute to efficacy. Our study raises the intriguing possibility that high levels of tumor cell VEGF-A, capable of both autocrine and paracrine interactions, are associated with resistance to bevacizumab, emphasizing the complexity of the tumor microenvironment.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab ; Carcinoma/diagnosis ; Carcinoma/drug therapy ; Carcinoma/genetics ; Disease Progression ; Disease-Free Survival ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Erlotinib Hydrochloride ; Female ; Gene Expression Regulation, Neoplastic/physiology ; Humans ; Likelihood Functions ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/genetics ; Platinum Compounds/therapeutic use ; Prognosis ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Treatment Outcome ; Tumor Microenvironment/genetics ; Up-Regulation/genetics ; Up-Regulation/physiology ; Vascular Endothelial Growth Factor A/genetics ; Vascular Endothelial Growth Factor A/metabolism ; Vascular Endothelial Growth Factor A/physiology
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Platinum Compounds ; Quinazolines ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V) ; Erlotinib Hydrochloride (DA87705X9K)
    Language English
    Publishing date 2010-11-01
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-10-0974
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top